Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)
Sponsor: University Health Network, Toronto
A PHASE2 clinical study on Cancer and Depression, this trial is completed. The trial is conducted by University Health Network, Toronto and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Apr 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Jun 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Sep 2018 — Jun 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Health Network, Toronto
For direct contact, visit the study record on ClinicalTrials.gov .